Positive Chrohn's Disease Results May Have Implications for Potential Lupus Drug
Monday, October 22, 2012
A clinical trial in the autoimmune disease Chrohn's Disease showed positive results for an experimental drug laquinimod that is also in development for lupus. Laquinimod is a novel oral immunomodulator in clinical development by Teva Pharmaceutical Industries and Active Biotech, for the treatment of multiple sclerosis (MS), Crohn's disease (CD) and systemic lupus erythematosus (SLE or lupus). The findings presented at a European medical meeting showed nearly 50% remission of Chrohn's Disease as compared to placebo.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms